HDR prostate brachytherapy plan robustness and its effect on in-vivo source tracking error thresholds: A multi-institutional study.
HDR
brachytherapy
in-vivo
prostate
robustness
source tracking
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
15
03
2022
received:
18
09
2021
accepted:
17
03
2022
pubmed:
8
4
2022
medline:
11
6
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
The purpose of this study was to examine the effect of departmental planning techniques on appropriate in-vivo source tracking error thresholds for high dose rate (HDR) prostate brachytherapy (BT) treatments, and to determine if a single in-vivo source tracking error threshold would be appropriate for the same patient anatomy. The prostate, rectum, and urethra were contoured on a single patient transrectal ultrasound (TRUS) dataset. Anonymized DICOM files were disseminated to 16 departments who created an HDR prostate BT treatment plan on the dataset with a prescription dose of 15 Gy in a single fraction. Departments were asked to follow their own local treatment planning guidelines. Source positioning errors were then simulated in the 16 treatment plans and the effect on dose-volume histogram (DVH) indices calculated. Change in DVH indices were used to determine appropriate in-vivo source tracking error thresholds. Plans were considered to require intervention if the following DVH conditions occurred: prostate V100% < 90%, urethra D0.1cc > 118%, and rectumtt Dmax > 80%. There was wide variation in appropriate in-vivo source tracking error thresholds among the 16 participating departments, ranging from 1 to 6 mm. Appropriate in-vivo source tracking error thresholds were also found to depend on the direction of the source positioning error and the endpoint. A robustness parameter was derived, and found to correlate with the sensitivity of plans to source positioning errors. A single HDR prostate BT in-vivo source tracking error threshold cannot be applied across multiple departments, even for the same patient anatomy. The burden on in-vivo source tracking devices may be eased through improving HDR prostate BT plan robustness during the plan optimisation phase.
Identifiants
pubmed: 35388456
doi: 10.1002/mp.15658
pmc: PMC9322430
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3529-3537Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.
Références
Phys Med Biol. 2021 May 05;66(10):
pubmed: 33831856
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):401-411
pubmed: 28341241
BJU Int. 2017 Jul;120(1):56-60
pubmed: 27628127
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1066-72
pubmed: 19616901
J Contemp Brachytherapy. 2016 Jun;8(3):201-7
pubmed: 27504129
Radiother Oncol. 2021 Jan;154:29-35
pubmed: 32918971
Clin Transl Radiat Oncol. 2020 Mar 27;23:20-26
pubmed: 32368626
Radiother Oncol. 2020 Dec;153:26-33
pubmed: 32987045
Radiother Oncol. 2014 Jan;110(1):110-3
pubmed: 24100150
Brachytherapy. 2018 Sep - Oct;17(5):788-793
pubmed: 29937206
Med Phys. 2020 Sep;47(9):4477-4490
pubmed: 32443175
Brachytherapy. 2019 Sep - Oct;18(5):711-719
pubmed: 31175015
Brachytherapy. 2018 Jan - Feb;17(1):111-121
pubmed: 28958735
Radiother Oncol. 2014 Jan;110(1):199-212
pubmed: 24299968
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):811-7
pubmed: 19836166
Med Phys. 2013 Jul;40(7):070902
pubmed: 23822403
Radiother Oncol. 2020 Oct;151:234-241
pubmed: 32828839
Phys Med Biol. 2005 Dec 7;50(23):5463-77
pubmed: 16306645
Med Phys. 2022 Jun;49(6):3529-3537
pubmed: 35388456
Radiother Oncol. 2017 Apr;123(1):125-132
pubmed: 28284493
Phys Med. 2019 Mar;59:30-36
pubmed: 30928063
Brachytherapy. 2018 Jan - Feb;17(1):122-132
pubmed: 28943129
Phys Imaging Radiat Oncol. 2020 Sep 28;16:1-11
pubmed: 33458336